We serve Chemical Name:2-methyl-2-(2-methylphenoxy)propanoic acid CAS:53498-62-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-methyl-2-(2-methylphenoxy)propanoic acid
CAS.NO:53498-62-7
Synonyms:2-methyl-2-(2-methylphenoxy)propanoic acid
Molecular Formula:C11H14O3
Molecular Weight:194.22700
HS Code:2918990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:302.8ºC at 760mmHg
Density:1.116g/cm3
Index of Refraction:1.523
PSA:46.53000
Exact Mass:194.09400
LogP:2.23700
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-methyl-2-(2-methylphenoxy)propanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methyl-2-(2-methylphenoxy)propanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-methyl-2-(2-methylphenoxy)propanoic acid Use and application,2-methyl-2-(2-methylphenoxy)propanoic acid technical grade,usp/ep/jp grade.
Related News: Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday. 2-methyl-2-(2-methylphenoxy)propanoic acid manufacturer Government prosecutors often consider whether a corporation made a genuine effort to investigate and address potentially illegal activities once learning of them. 2-methyl-2-(2-methylphenoxy)propanoic acid supplier The company’s product reserves are rich, with more than one hundred varieties in various categories from intermediates to APIs. At present, the grays and anti-hepatitis C series intermediates are steadily advancing, which will ensure future growth. 2-methyl-2-(2-methylphenoxy)propanoic acid vendor Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday. 2-methyl-2-(2-methylphenoxy)propanoic acid factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.
